Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting

SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastroi...

Related Keywords

Sydney ,New South Wales ,Australia ,Guangzhou ,Guangdong ,China ,Japan ,Singapore ,Hong Kong ,Yokohama ,Kanagawa ,Prnewswire Arbele ,Dennis Wong ,Business Development ,Chief Medical Officer ,Investor Contact ,Diana Hay ,